Related Experiment Video
Updated: May 26, 2026
19:15
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
[Psychotropics, pregnancy, lactation and neurodevelopmental issues: a review]
J Lancini1, P Linkowski, S Leistedt
1Département de Psychiatrie, Hôpital Erasme, Bruxelles. jlancini@ulb.ac.be
Revue Medicale De Bruxelles
|December 15, 2011
Summary
Psychotropic medication use during pregnancy and postpartum poses risks to fetal development and maternal health. More research is needed to identify safer options for childbearing women
Area of Science:
- Perinatal mental health
- Pharmacology
- Developmental toxicology
Context:
- Mental health stability is crucial for childbearing women during pregnancy and postpartum.
- Psychotropic medications can cross the placenta and enter breast milk, posing risks to the fetus.
- Existing data on the safety of psychotropic use during pregnancy and lactation is limited.
Purpose:
- To review the medical literature of the past ten years regarding psychotropic medication use in pregnant and lactating women.
- To identify psychotropic medications that may minimize risks to the fetus while managing maternal morbidity.
- To assess the current state of knowledge on the safety and developmental outcomes of children exposed to these medications.
Summary:
- The safety of psychotropic medication use during pregnancy and lactation remains an unresolved issue.
- Information on the developmental outcomes of children exposed to psychotropic medications, particularly newer ones, is scarce.
- Recent case reports show encouraging signs, but larger, standardized studies are essential.
Impact:
- Highlights the critical need for more comprehensive research into the safe use of psychotropic medications during pregnancy and lactation.
- Emphasizes the ongoing challenge of balancing maternal mental health treatment with fetal safety.
- Underscores the necessity of evidence-based guidelines for clinicians treating pregnant and postpartum women with mental health conditions.
More Related Videos
06:39Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants
Published on: June 13, 2021
05:13Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
Published on: February 28, 2025
Related Concept Videos
01:21Factors Affecting Drug Response: Overview
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...